Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5453-5459

  Gebhardt, Christoffer ^a   Sevko, Alexandra ^a   Jiang, Huanhuan ^a,b   Lichtenberger, Ramtin ^a   Reith, Maike ^a   Tarnanidis, Kathrin ^a   Holland Letz, Tim ^c   Umansky, Ludmila ^c   Beckhove, Philipp ^c   Sucker, Antje ^c,d   Schadendorf, Dirk ^c,d   Utikal, Jochen ^a   Umansky, Viktor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; EOTAXIN; HIGH MOBILITY GROUP B1 PROTEIN; IPILIMUMAB; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; AUTACOID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CANCER STAGING; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SURVIVAL TIME; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOPHENOTYPING; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; MYELOID CELLS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84954143592     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0676     Document Type: Article

References (32)

1. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27.
2. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
3. Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012;22:319-26.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 2011;11:805-12.
6. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011;108:16723-8.
7. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-94.
8. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12.
9. Gabrilovich DI,Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
10. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013;1:158-62.
11. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014;63:247-57.
12. Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges 2014;12:1021-7.
13. Grivennikov SI, Greten FR, KarinM. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
14. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb-e C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
15. Kiessling R, Mao Y, Pico de Coana Y. Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells. Clin Cancer Res 2014;20:1401-3.
16. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012;61:255-63.
17. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloidderived suppressor cells. J Immunol 2008;181:4666-75.
18. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, BuiMM,et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49.
19. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 2014;74:5723-33.
20. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: Implications for human disease. Mol Med Today 2000;6: 20-27.
21. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013;24:1697-703.
22. Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res 2014;2:1-8.
23. Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): Role in the inflammatory response within tumors. J Immunother 2007;30:16-28.
24. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015;16:609-17.
25. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013;23:200-7.
26. Weide B, Martens A, Zelba H, Derhovanessian E, Bailur JK, Kyzirakos C, et al. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: Comparison with regulatory T cells and NY-ESO-1-or Melan-A-specific T cells. Clin Cancer Res 2014;20:1601-9.
27. Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 2015;136:2352-60.
28. Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, et al. Computational algorithm-driven evaluation of monocytic myeloidderived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014;2:812-21.
29. Gebhardt C, N-emeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006;72:1622-31.
30. Kang R, Zhang Q, Zeh HJ 3rd,Lotze MT, Tang D. HMGB1 in cancer: Good, bad, or both? Clin Cancer Res 2013;19:4046-57.
31. Gebhardt C, Riehl A, Durchdewald M, N-emeth J, Furstenberger G, Muller-Decker K, et al.RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275-85.
32. Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer 2015 May 27. [Epub ahead of print].